Form 4: Kodiak Sciences CFO John A. Borgeson Reports Stock Sale to Cover Tax Obligations

John A. Borgeson, CFO of Kodiak Sciences, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On June 11, 2024, John A. Borgeson, the CFO of Kodiak Sciences, vested 3,025 restricted stock units (RSUs).
• To cover tax withholding obligations associated with the vesting of these RSUs, Borgeson sold 1,558 shares of common stock on June 12, 2024, at a price of $2.92 per share.
• Following these transactions, Borgeson directly owns 179,544 shares of Kodiak Sciences common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This Form 4 filing is a routine disclosure of stock transactions by a company insider, which is common in the biopharmaceutical industry. It provides transparency into the trading activities of key personnel.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, including competitors like Regeneron, Alnylam Pharmaceuticals, and Biogen.
• The sale of shares to cover tax obligations is a common occurrence among executives receiving equity compensation, aligning with industry norms.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders due to the increased supply of shares, but it is unlikely to be significant given the relatively small volume.
• The transaction has no direct impact on employees, customers, suppliers, or creditors.

Key Dates